公开(公告)号：US20240216430A1

公开(公告)日：2024-07-04

申请号：US18521196

申请日：2023-11-28

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Zhe LI ,  Siler PANOWSKI ,  Barbra Johnson SASU ,  Bryan A. SMITH ,  Thomas John VAN BLARCOM ,  Tao SAI ,  Guoyun ZHU

IPC: A61K35/17 ,  A61K39/00 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464438 ,  C07K16/2875 ,  A61K2039/505 ,  A61K2239/13 ,  A61K2239/17 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/23 ,  A61K2239/29 ,  A61K2239/31 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622

Abstract: Provided herein are Claudin 18.2 binding agents and chimeric antigen receptors (CARs) comprising a Claudin 18.2 binding molecule that specifically binds to Claudin 18.2; and immune cells comprising these Claudin 18.2-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using Claudin 18.2-specific CARs and Claudin 18.2 binding agents, and immune cells comprising Claudin 18.2-specific CARs.

公开(公告)号：US20200331998A1

公开(公告)日：2020-10-22

申请号：US16851691

申请日：2020-04-17

Applicant: ALLOGENE THERAPEUTICS, INC.

Inventor： Thomas Charles PERTEL ,  Barbra Johnson SASU ,  Tao SAI

IPC: C07K16/28 ,  A61K35/17

Abstract: Provided herein are isolated antibodies that specifically bind anti-CD19 chimeric antigen receptors (CARs) derived from a 4G7 scFv. Also provided are methods of making and using these isolated antibodies.

公开(公告)号：US20250011446A1

公开(公告)日：2025-01-09

申请号：US18639749

申请日：2024-04-18

Applicant: Pfizer Inc.

Inventor： Siler PANOWSKI ,  Tao SAI ,  Barbra Johnson SASU ,  Surabhi SRIVATSA SRINIVASAN ,  Thomas John VAN BLARCOM

IPC: C07K16/28 ,  A61K39/00 ,  A61P35/00

Abstract: The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.

公开(公告)号：US20230041456A1

公开(公告)日：2023-02-09

申请号：US17843616

申请日：2022-06-17

Applicant: Pfizer Inc.

Inventor： Surabhi SRIVATSA SRINIVASAN ,  Niranjana NAGARAJAN ,  Siler PANOWSKI ,  Yoon PARK ,  Tao SAI ,  Barbra SASU ,  Thomas VAN BLARCOM ,  Mathilde DUSSEAUX ,  Roman GALETTO

IPC: C07K16/28 ,  A61K39/00 ,  C07K14/725 ,  A61P35/02 ,  A61P35/04

Abstract: The disclosure provides CARs (CARs) that specifically bind to CD70. The disclosure further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The disclosure further relates to therapeutic methods for use of these CARs and engineered immune cells comprising these CARs for the treatment of a condition associated with malignant cells expressing CD70 (e.g., cancer).